AB0763 Personal approach in axial spondyloarthropathy management

Background Spondyloarthropathies (SpAs) are a group of diseases characterized by arthritis in the spine (axialSpA - axSpA) and peripheral joints, extra-articular symptoms like uveitis, psoriasis or inflammatory bowel diseases. The onset disease is difficult to observe. Due lack pathognomonic test, diagnosis based on combination physical examination, laboratory test imaging results. pathogenesis SpAs not fully understood, genetic, environmental immunological factors assumed play pivotal role. Objectives study aimed evaluate selected polymorphisms (ERAP1 rs2287987, ERAP2 rs2549782, TNF rs1800629, TNFRSF1B rs1061622, FCGR2A rs1801274) as prognostic clinical presentations, response predictors anti-TNF treatment axSpA patients. Methods enrolled 216 Caucasians: 106 patients 110 healthy controls. AS were diagnosed according modified New York criteria, while nr-axSpA ASAS criteria. Genotyping was performed using LightSNiP assays Real-Time PCR Instrument. Clinical data assessed at baseline, well after three six months treatment. In addition, information’s about collected. Results statistical analysis revealed that rs1061622-GG significantly associated with higher VAS score baseline (TT + TG vs GG, p = 0.001), BASDAI corrected for first therapy cycle (X1C BASDAI: TT 0.005). Moreover, homozygotes more frequently observed improvement TT+GG TG, 0.045, OR 2.46, 95%CI 1.00-6.12). ERAP1 rs2287987- GG enthesitis (AA G+, 0.049, 4.636, 1.101-21.24). genotype rs1061622 common uveitis than variant (GG TT, =0.042, 5, 1.08-20). Associations between genetic variants outcomes evaluated parameters. A ESR within rs2287987-AG (AG AA 0.027, 2.72, 1.115-6.137) rs1061622- 0.020, 3, 1.27-6.9) compared other genotypes. After therapy, rs2549782 polymorphism among individuals T allele carriers T+, 0.037, 2.76, 1.13-6.72). Differences also detected rs1801274 X1CBASDAI months. low activity (BASDAI < 3) carrying (AA+AG 0.028, 4.545, 1.337-16 0.012, 6.212, 1.683-20.47, respectively). AG remission 2) AA+GG, 0.046, 2.36, 1.05-5.13). Conclusion Genetic profiling will help identify those risk high initial presence symptoms. Identifying less responsive may allow selecting drug an appropriate efficacy profile. Acknowledgements This work supported grant from Wroclaw Medical University (Poland) STM.A270.20.153. Disclosure Interests Bartosz Bugaj: None declared, Joanna Wielinska: Jerzy Swierkot Speakers bureau: For Abbvie, Roche, Lilly, Sandoz, Pfizer, Medac, MSD, Novartis, UCB, Katarzyna Bogunia-Kubik: declared